Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application to proceed with a randomized, double-blind, placebo-controlled Phase 2 trial of Lucid-MS in patients with multiple sclerosis (MS). The announcement, featured in BioMedWire editorial coverage, highlights a significant milestone for the company’s lead drug candidate, which is designed to target the underlying mechanisms of demyelination rather than broadly suppressing the immune system like many current MS therapies.
Lucid-MS, also known as Lucid-21-302, is a patented, first-in-class drug candidate that inhibits peptidyl arginine deiminase 2 (PAD2). By targeting demyelination—the process that damages the protective myelin sheath around nerve fibers—Lucid-MS aims to address the root cause of MS progression. The drug has previously completed Phase 1 testing in healthy volunteers, where it demonstrated favorable safety and tolerability, according to the company.
The clearance allows Quantum BioPharma to begin the first clinical testing of Lucid-MS in people with MS, a critical step in advancing the drug toward potential regulatory approval. The Phase 2 trial will evaluate the drug’s efficacy and safety in a larger patient population, providing essential data on its therapeutic potential.
In parallel, Quantum BioPharma is collaborating with scientists at Massachusetts General Hospital and Harvard Medical School on research involving a PET imaging tracer designed to quantify demyelination. This collaboration could enhance the ability to measure the drug’s effect on myelin repair in clinical trials, potentially accelerating the development process.
The editorial coverage also notes recent analyst attention on Quantum BioPharma. Rodman & Renshaw has initiated coverage with a Buy rating and an $8 price target, reflecting confidence in the company’s prospects. This comes as Quantum BioPharma prepares to advance Lucid-MS into a pivotal phase of development.
The broader biopharmaceutical landscape is also active in neurological diseases, with companies like Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB), and Clene Inc. (NASDAQ: CLNN) pursuing various approaches. Quantum BioPharma’s focus on a first-in-class oral therapy that directly targets demyelination could differentiate it in a competitive market.
The importance of this FDA clearance lies in the potential for Lucid-MS to offer a new treatment option for MS patients. Current therapies often modulate the immune system to reduce inflammation, but they do not necessarily promote myelin repair. By directly targeting the process of demyelination, Lucid-MS could potentially slow or reverse disability progression, a major unmet need in MS care.
For more information on the full press release, visit https://ibn.fm/cwPHa. For the latest news and updates on Quantum BioPharma, see the company’s newsroom at https://ibn.fm/QNTM.
